These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17621463)

  • 1. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.
    Cassetti I; Madruga JV; Suleiman JM; Etzel A; Zhong L; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(3):164-72. PubMed ID: 17621463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
    Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
    Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
    HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
    J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
    Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T;
    HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
    Della Negra M; De Carvalho AP; De Aquino MZ; Pinto JA; Da Silva MT; Andreatta KN; Graham B; Liu YP; Quirk EK
    Pediatr Infect Dis J; 2015 Apr; 34(4):398-405. PubMed ID: 25599284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.